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Abstract: Purine nucleotides are involved in a multitude of cellular processes, and the dysfunction of
purine metabolism has drastic physiological and pathological consequences. Accordingly, several genetic
disorders associated with defective purine metabolism have been reported. The etiology of these
diseases is poorly understood and simple model organisms, such as yeast, have proved valuable to
provide a more comprehensive view of the metabolic consequences caused by the identified mutations.
In this review, we present results obtained with the yeast Saccharomyces cerevisiae to exemplify how
a eukaryotic unicellular organism can offer highly relevant information for identifying the molecular
basis of complex human diseases. Overall, purine metabolism illustrates a remarkable conservation of
genes, functions and phenotypes between humans and yeast.
Keywords: purine metabolism; nucleotide synthesis; purine-associated deficiencies; hyperuricemia;
Lesch–Nyhan; AMP-deaminase; ATIC; ADSL; PRPS
1. Introduction
Purine nucleotides, adenosine 5’-triphosphate (ATP), guanosine 5’-triphosphate (GTP) and their
derivatives are involved in a myriad of cellular processes: energy storage, synthesis of nucleic acids
and coenzymes (Nicotinamide adenine dinucleotide (NAD)/Nicotinamide adenine dinucleotide
phosphate (NADP)/coenzyme A/flavine adenine dinucleotide (FAD)), translation, signaling, etc.
These molecules are thus absolutely required for all known forms of life, and their synthesis
results essentially from conserved pathways. In yeast, mutations abolishing ATP or GTP synthesis
are lethal, although lethality may require more than one mutation due to genetic and pathway
redundancy [1]. Even a partial block of purine metabolism can have drastic physiological
consequences, and several diseases associated with purine metabolism dysfunctions have been
reported in human [2–5]. Some purine metabolic disorders have been described for a long time,
such as hyperuricemia (gout), which is caused by an excess of uric acid (the final purine degradation
product) leading to a painful deposit of urate crystals in joints. Among the studies of genetic
alterations leading to hyperuricemia, hypoxanthine phosphoribosyl transferase (HGPRT)-deficiency,
involved in the Lesch–Nyhan syndrome, was one of the very first genetic-disease enzymes
identified in humans [6]. In addition to hyperuricemia, purine metabolism-associated diseases
share a large spectrum of immunological, hematological and neuro-muscular disorders [7], and are
all characterized by an abnormal level of purine nucleotides in cells and of nucleosides and/or
nucleobases in bodily fluids [8]. In most cases, the dysfunctional gene in purine metabolism is known.
However, this identification of the causative enzyme does not necessarily give clear indications on
the etiology of the disease and hence, a more comprehensive view of the metabolic consequences
of the dysfunction is often needed. To this end, model organisms that are amenable to genetics
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can be valuable for identifying critical functions that are affected as a consequence of the primary
metabolic dysfunction. Several animal or microbial models can be used for this purpose and are
often highly complementary. In this review, we present results obtained with the budding yeast,
Saccharomyces cerevisiae, to illustrate how a unicellular eukaryotic organism can offer highly relevant
information to help understand the mechanisms leading to complex human diseases.
Yeast can be both a source of information and a tool used to study human metabolic diseases.
In both cases, the relevance of the information drawn from yeast depends on the functional
conservation between yeast and humans, a conservation which is often much higher than one could
have initially thought based on their long divergent evolution (over one billion years). In a systematic
replacement of yeast genes by their human orthologues, Marcotte and coworkers showed that nearly
half of the yeast genes could be successfully “humanized” [9], thus confirming the wide potential
of yeast as a model to study diseases associated to human gene dysfunctions. As a unicellular
eukaryotic organism yeast is a very polyvalent tool, since it is highly amenable to molecular genetics
but also to analytical biochemistry. Studies on yeast have provided a multitude of information
on metabolic pathways and how they are connected with one another as well as to other cellular
functions. In addition, as an organism facing nutrient changeability and stress [1], it also delivered
key information on how metabolic homeostasis is achieved in complex systems. This integrated view
offered by yeast research is of great value to help address complex metabolic diseases in human.
Indeed, most diseases are the result of multiple effects and take place in a highly integrated genetic
and physiological context. Knowledge collected from yeast can be used to generate testable hypotheses
in human cells or model animals.
In this review, we will focus on purine metabolic diseases and illustrate how yeast can be used
to help promote our understanding of the mechanisms involved. As stated above, yeast can be
used as a model provided that sufficient functional conservation is found. However, to be highly
informative as a model, yeast should demonstrate both conservation of enzymes and pathways,
as well as a conserved functional organization including interactions between the metabolic pathways.
This last aspect cannot be generalized and requires thorough specific investigations. Several examples
developed below illustrate the remarkable level of conservation in the “logic” of metabolism and in
the consequences of its dysfunctions. This suggests that the general mechanisms responsible
for nucleotide homeostasis are very ancient and that their conservation has been under high
selective pressure.
2. Purine Metabolism in Human and Yeast: Similarities and Differences
Purine Metabolic Pathways: Functions Are Generally Conserved but Protein Sequences Can Diverge
Most enzymatic steps of the purine de novo and recycling pathways are catalyzed by proteins
that are largely conserved between prokaryotes and eukaryotes [1]. Accordingly, a high degree
of conservation is found between yeast and human purine pathways. The ten enzymatic steps of
the de novo pathway are fully conserved, although the percentage of identity among orthologous
enzymes is variable, as illustrated in Figure 1. Remarkably, the four most conserved proteins
(>60% identity between orthologs) in the de novo and downstream pathways are mutated in reported
diseases (Figure 1, blue arrows), i.e., Phosphoribosyl pyrophosphate (PRPP) synthetase (PRPS1);
adenylosuccinate lyase (ADSL), aminoimidazole carboxamide riboside monophosphate transformylase
inosine 5’-monophosphate cyclohydrolase (ATIC) and IMP dehydrogenase (IMPDH) (Table 1). Of note,
both the ADSL and ATIC steps metabolize intermediates acting as regulators of various functions
in both yeast and humans (see below, Section 3.2) [10–14]. A lower identity is detected for proteins
catalyzing the seven other steps of the de novo pathway, and several of these enzymes are encoded
as gene fusions in the human genome (see GART and PAICS, Figure 1). For the purine salvage
pathway, conservation varies between the nucleotide monophosphate interconversion enzymes
and the nucleoside/nucleobase salvagers. Indeed, the interconversion of monophosphate nucleotides
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is ensured by highly conserved proteins, while enzymes metabolizing nucleosides and nucleobases
show little to no conservation (Figure 1). Among those enzymes, the first group corresponds
to proteins that are highly divergent in sequence but for which catalytic activity is nevertheless
conserved. These proteins correspond to the phosphoribosyl transferases (APRT and HGPRT, Figure 1),
which catalyze nucleotide monophosphate synthesis from nucleobases, and to the nucleosidases
(Phm8 [15] and Isn1 [16] in yeast and the NT5 nucleotidase family in human [17]) that catabolize
nucleotide monophosphate to nucleosides. The second group contains proteins with no orthologs
between yeast and humans. For example, in humans, adenosine is deaminated into inosine by
ADA [18] with no yeast ortholog and, by contrast, the yeast adenine deaminase (Aah1) catalyzing
adenine to hypoxanthine conversion [19] has no ortholog in human cells (Figure 1). Of note,
this difference in the evolution of nucleobase and nucleoside metabolism in yeast versus humans
is strengthened by the fact that nucleobases are the only purine precursors taken up by yeast [1]
via the concentrative carrier Fcy2 [20], while nucleobases and nucleosides are both transported into
human cells by a set of equilibrative (hENT) and concentrative (hCNT) membrane transporters [21].
Another major difference observed between yeast and humans relates to purine degradation.
In humans, nucleobases are transformed to uric acid by xanthine oxidoreductases [8], while in yeast,
removal of purine excess is performed by nucleobase excretion (essentially hypoxanthine) [13,22,23].
Indeed, no xanthine oxidase activity has been reported in yeast. By contrast, the other purine
degradation steps which are common to both yeast and humans correspond to purine nucleoside
phosphorylase (inosine to hypoxanthine transformation by PNP/Pnp1) and guanine deaminase
(guanine to xanthine metabolization by GAH/Gud1), which are both well conserved between yeast
and humans (Figure 1).
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Figure 1. Schematic representation of the human and Saccharomyces cerevisiae purine biosynthesis
pathways. Features of human and yeast enzymes are listed in Table A1, Table A2 and are shown in
black and pink, respectively. For human enzymes, the numerous isoforms detected for some enzymes
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“ATP production” in both yeast and human cells corresponds to the different ATP production pathways
such as glycolysis and the respiratory chain/ATP synthase complexes. “Nucl.” stands for the numerous
human nucleotidases, such as for example the NT5 family. Abbreviations: IMP: Inosine monophosphate;
PRPP: Phosphorybosyl pyrophosphate; SAMP: Succinyl-AMP; SZMP: Succinyl Amino Imidazole
Carboxamide Ribonucleotide monophosphate; XMP: Xanthosine monophosphate; ZMP: Amino Imidazole
CarboxAmide Ribonucleotide monophosphate.
Table 1. Pathologies associated with defects in purine synthesis enzymes highly conserved between
yeast and humans.
Pathology EnzymaticDefect
Gene Name
(Location)
Phenotype
MIM Number Inheritance
Locus MIM
Number Reference
ADSL deficiency Loss offunction
ADSL
(22q13.1) 103050
Autosomal
recessive 608222 [24]
AICA-Ribosiduria Loss offunction
ATIC
(2q35) 608688
Autosomal
recessive 601731 [25]
Retinitis pigmentosa 10 Loss offunction
IMPDH1
(7q32.1) 180105
Autosomal
dominant [26]
Leber Congenital Amaurosis 11 Loss offunction
IMPDH1
(7q32.1) 613837 ? 146690 [27]
PNP deficiency PNP(14q11.2) 613179
Autosomal
recessive 164050 [28]
Arts syndrome Loss offunction
PRPS1
(Xq22.3) 311835
X-linked
recessive 311850 [29]
Charcot-Marie-Tooth disease,
X-linked recessive, 5
Loss of
function
PRPS1
(Xq22.3) 311070
X-linked
recessive 311850 [30]
Deafness, X-linked 1 Loss offunction
PRPS1
(Xq22.3) 304500 X-linked 311850 [31]
Hyperuricemia, PRPS-related Gain offunction
PRPS1
(Xq22.3) 300661
X-linked
recessive 311850 [32]
In summary, this comparison highlights that the purine-associated human diseases correspond
to alterations in the most conserved steps of the purine pathways (Figure 1, blue arrows).
When altered, these steps are also detrimental in yeast and belong to the following pathways:
(1) The monophosphate interconversion pathway which is common to the de novo and salvage
pathways (downstream pathway), which allows interconversion between purines and the balanced
synthesis of the final products ATP and GTP (Figure 1), (2) the phosphoribosyl pyrophosphate (PRPP)
synthesis which is required for both the de novo pathway (for PPAT/Ade4) and the salvage pathway
(for the phosphoribosyl transferases APRT and HGPRT) and (3) purine degradation (via PNP/Pnp1).
In most of these purine-associated diseases, however, it is not clear whether the detrimental effects are
linked to a toxic accumulation of the substrate(s) of these enzymes, to a lack of their products, or to
a combination of both effects. The high degree of conservation observed between the two organisms
allows us to use yeast genetics to address these issues and raise hypotheses testable in human cells or
small animal models.
3. Yeast: A Model to Tackle Complex Purine-Associated Diseases
Metabolic genetic diseases most often affect metabolic enzymes which in the mutant form is either
inactive (loss of function), hyperactive or inadequately regulated. These dysfunctions can result in
different metabolic consequences which are not at all exclusive:
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• Important metabolites may not be synthesized, or synthesized insufficiently
• Metabolites, which are accumulated due to an increased synthesis or the lack of metabolizing
enzymes, can be toxic because they interfere with other processes (this could be particularly true
for metabolites which have physiological regulatory properties)
• A metabolic unbalance can occur, which is often due to a mix of the first two hypotheses
In many instances, mutations in yeast and human orthologues not only result in the same
biochemical dysfunction (typically loss of activity) but also may lead to highly similar secondary
consequences. Below, using various examples, we will illustrate the issues raised by complex metabolic
diseases and how yeast can help to address these.
3.1. AMP-Deaminase (AMPD2) Deficiency Associated with Pontocerebellar Hypoplasia Results in Defective
ATP/GTP Balance
AMP-deaminase is an important purine interconversion enzyme, which allows synthesis of
IMP from AMP (Figure 1). In yeast there is a unique isoform encoded by the AMD1 gene, while in
humans there are three isoforms expressed in different tissues. Deficiency of the muscular form,
AMPD1, is associated with hyper-fatigability and is a relatively frequent mutation, although it is often
asymptomatic, which suggests complex interplays with other factors [8]. The lack of the yeast enzyme
was associated with an increased ATP and low GTP under conditions where ATP was synthesized
from adenine. In the meantime, the nucleotide balance was unaffected when amd1-deleted yeast
cells were grown under conditions where ATP was synthesized from IMP [33]. This conditional
phenotype lead to the conclusion that the low GTP was a result of ATP accumulation, which occurred
through an ATP feedback inhibition of Ade4, the first enzyme of the de novo pathway [13].
This allosteric inhibition resulted in a lowered IMP synthesis and consequently a low intracellular
GMP and GTP [33]. More recently, the identification in humans of AMPD2 deficiency as the cause of
pontocerebellar hypoplasia in a cohort of patients revealed that the exact same phenomenon operated
in human cells [34]. These authors showed that, just as in yeast, the GTP shortage in AMPD2 deficient
human cells was dependent on replenishment of the adenylic nucleotide pool by a purine precursor
(adenosine for human cells, adenine for yeast) [33,34]. In both cases, ATP accumulation resulted in
a low GTP, through regulatory means. Thus, in the AMP deaminase-deficient cells, ATP was toxic by
affecting the ATP/GTP balance in both yeast and human cells. Accordingly, restoring intracellular GTP
through guanine or AICAR feeding in yeast and human cells, respectively, was sufficient enough to
abolish ATP toxicity [33,34]. This illustrated how a single mutation could cause a complex phenotype
through shortage of the reaction product (IMP), accumulation of the substrate (AMP) and the resulting
imbalance of downstream metabolic products (ATP and GTP).
In their study, Akizu and coworkers also took advantage of yeast to functionally validate
AMPD2 as an AMP deaminase by complementation of the amd1 growth defect specifically on adenine.
They also expressed Human AMPD2 mutant forms in yeast cells and showed that these alleles
resulted in poorly functional enzymes [34]. Finally, these authors identified translation initiation
as a defect resulting from GTP shortage, in both humans and yeast, and proposed that it could
contribute to the etiology of this disease [34]. Importantly, once again yeast was used to document
this phenomenon in depth [34]. This study thus nicely illustrates not only how information derived
from yeast genetics can be used to characterize a human disease, but also how yeast can be used
as a tool to functionally validate the various alleles of a human gene or to study molecular mechanisms
that could cause the disease. The authors proposed that the dependence on adenosine for expression of
the phenotype could explain the neural-specificity of the defect, since a significant amount of adenosine
was present in the brain [35]. Hence, “brainless” yeast proved to be very useful for understanding this
neurodegenerative disorder. More generally, this work exemplifies the remarkable conservation of
genes, functions, phenotypes and mechanisms between human and yeast.
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3.2. Deficiencies in the Purine De Novo Pathway: Toxic Accumulation of Metabolic Intermediates?
Strikingly, while a succession of 13 enzymatic steps are required for AMP de novo synthesis, so far
mutations in only three of the corresponding genes have been identified as associated with diseases.
These three genes encode phosphoribosyl pyrophosphate synthase (PRPS) [29–32], adenylosuccinate
lyase (ADSL) [36] and AICAR-transformylase IMP cyclohydrolase (ATIC) [25]. The reasons why
no disease has ever been associated with mutations in the other steps of the de novo pathway are
not known, but it is remarkable that SZMP (Succinyl Amino Imidazole Carboxamide Ribonucleotide
monophosphate) and ZMP (Amino Imidazole Carboxamide ribonucleotide monophosphate),
the substrates of both ADSL and ATIC respectively (Figure 1), were identified as two major regulator
metabolites in yeast [12–14]. This suggests that the disease caused by the enzymatic defect could
mostly be due to a toxic accumulation of the enzyme-substrates and/or derivatives, rather than by
the block in the de novo pathway.
For ADSL, the situation is even more complex as this enzyme acts at two different steps
of AMP synthesis and its defect leads to accumulation of its two substrates, SZMP and SAMP
(Succinyl AMP). Both metabolites are suspected to contribute to the etiology of the disease, and their
relative abundance was proposed to be relevant for symptom severity [37,38], although this
assumption is still debated [39,40]. Yeast genetics (our unpublished results) revealed that the ADSL
knock-out mutants were genetically unstable and tended to pick-up suppressor mutations upstream
in the de novo pathway that would block substrate accumulation. Indeed, in yeast, under conditions
where the pathway is constitutively turned-on, SZMP and/or SAICAR (Succinyl Amino Imidazole
Carboxamide Ribonucleoside) toxicity clearly correlated to the strength of the allele i.e., to the level
of residual ADSL activity [14]. The reasons for SZMP/SAICAR toxicity are not elucidated, but could
be related to the regulatory roles of this small molecule. In yeast, SZMP promotes an interaction
between two transcription factors, Bas1 and Pho2, and thereby stimulates transcription of the purine
regulon [12], while in humans, SZMP specifically stimulates PKM2 in cancer cells [11].
ATIC deficiency is a very rare disease that leads to a massive accumulation of AICAR
monophosphate (ZMP) [25]. In yeast, ATIC mutants (the ade17 mutant and ade16 ade17 double
mutant) massively accumulate ZMP but also the other nucleosides (AICAR (Amino Imidazole
Carboxamide ribonucleoside), SAICAR and Succinyl-adenosine) and nucleotide monophosphate
derivatives (SZMP and SAMP). We have shown that an enzymatic inhibition and/or reversion of ADSL
(Ade13) by ZMP are responsible for the accumulation of these succinyl derivatives in yeast [12,13].
It could be then expected that the accumulation of these derivatives also observed in ATIC patients [25]
could be linked to a similar phenomenon. Yeast thus offers genetic and biochemical tools that can help
identify some sources of toxicity for those AICAR derivatives. Indeed, by proteomic approaches,
we have recently identified yeast proteins that specifically bind ZMP and some of its derivatives
(AICAR, SZMP and AMP) [41]. A similar approach was also performed with mammalian proteins
(human cells; M. Duperray, M. Moenner and B. Pinson, unpublished results) and revealed 104 human
proteins specifically binding the ZMP resin. Among those human proteins, 70 have a yeast ortholog of
which one third were previously identified as specific ZMP binders [41]. Molecular studies of the ZMP
effect on some of these proteins can provide new insights into the biological defects associated with
human ADSL and/or ATIC deficiencies.
Strikingly, AICAR and ZMP also accumulate in other human purine-associated diseases
such as in HGPRT deficiency [42,43], and this was also observed in hpt1 mutant yeast
cells [44], suggesting once again a high functional conservation of the metabolic balances in
the two organisms. Importantly, a HGPRT deficiency in yeast was synthetically lethal with
ZMP accumulation [45], suggesting that the small molecule could contribute to the etiology
of the disease. Interestingly, our genetic analyses of yeast revealed mutations in GMP kinase
(Guk1, Figure 1) that mimicked the HGPRT deficiency phenotypes: hypoxanthine utilization, purine
excretion [23] and also ZMP accumulation [44]. Whether a similar phenocopy mechanism exists in
human and which could account for some of the “non-HGPRT-dependent HGPRT-like deficiencies”,
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remains to be investigated. How and to what extend ZMP accumulation contributes to the pathological
symptoms associated with HGPRT-deficiency remains to be established, but this hypothesis has been
raised in the past [46].
Interestingly, in yeast, while both ZMP and SZMP are toxic [14], ZMP appeared to be more
toxic than SZMP since synthesis of SZMP from ZMP increased AICAR-resistance, while on the other
hand blocking synthesis of SZMP from ZMP increased AICAR sensitivity [41]. Beside its potential
implication in purine metabolic diseases as a toxic metabolite, AICAR is used as an antiproliferative
prodrug. Indeed, AICAR is toxic for tumor cells of multiple origins [47] and in particular to aneuploid
cells [48,49] thus raising interesting perspectives as an anticancer molecule. Importantly, it was well
tolerated in phase I/II clinical trials [50] and has proved efficient in several different xenograft
assays [48,51,52]. Yeast genetics has been used to identify the sources of sensitivity and resistance
to AICAR, including uptake [53], carbon utilization [45], nuclear import [41,54] and the ubiquitin
pathway [55]. Importantly, based on the results obtained in these yeast studies, we found that AICAR
toxicity was increased in the knock-down of human genes (RNF40, ASH2L, MLL2) corresponding
to the yeast mutations (bre1, set1) [54]. Hence yeast, besides being a model for purine metabolic
diseases, can also be used to reveal genetic backgrounds specifically affected by drugs, including toxic
nucleoside analogs such as AICAR [56] or purine metabolism inhibitors such as mycophenolic acid [57],
an IMPDH inhibitor which is used as an immunosuppressant in clinics.
4. Yeast as a Tool to Functionally Validate Orthologous Genes from Other Model Organisms
Though yeast studies can be very informative about molecular mechanisms associated with purine
metabolism diseases, animal models are required to study tissue specific or developmental aspects
that are the most likely determinant in the etiology of purine metabolism diseases. While mice have
been used as a model animal, for example to study HGPRT deficiency [58], new models are emerging
that are more prone to developmental studies due to external development such as the zebra fish [59]
or Xenopus laevis (our unpublished work), or more open to the possibility of running genetic
experiments (nematode, [60]). Although the genomes of these organisms are fully sequenced, very little
is known about their purine metabolism. As a first step it is essential to identify the purine metabolism
coding genes (classically by homology search) and most importantly to validate them functionally.
This functional validation can be done by complementation of the corresponding knock-out mutants
in yeast. Our unpublished work on X. laevis and on the nematode Caenorhabditis elegans allowed
such a functional validation for most of the candidate purine metabolism genes via their expression
in yeast. As an illustration, the paics1.L X. laevis gene restored growth of an ade1 knock-out yeast
mutant in the absence of external purine (Figure 2 and our unpublished results) or for C. elegans gene
candidates [60]. Yeast can also be used for in vivo studies of the effects of mutations in human genes,
as was done for example for APRT [61]. Hence, yeast not only proved useful as a model by itself
but also to help set up new models more disposed to addressing specific questions such as tissue
specificity or developmental aspects. Taking advantage of the complementarity of various models
has been a fruitful strategy for tackling highly integrated biological questions, and for providing some
understanding about complex human diseases. In this respect, yeast has very efficiently played its part,
and will certainly continue to help us address challenging questions in the future.
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Figure 2. Functional complementation of the yeast phosphoribosyl aminoimidazole
succinocarboxamide synthetase by the Xenopus laevis ortholog paics1.L. (a). Simplified scheme of
the yeast purine pathway. (b). Yeast wild-type and knock-out mutant (ade1∆) strains were either
transformed with a plasmid allowing expression of the yeast (ADE1 Sc) or the Xenopus laevis (paics 1.L)
amino imidazole succinocarboxamide synthetase encoded gene, or with the empty vector (None).
Serial dilutions (1/10) of transformants were dropped on SDCASAW medium to score the ability of
the yeast and xenopus genes to complement the ade1 mutant auxotrophy observed in the absence
of external purine source. A medium supplemented with adenine was used as a viability control of
transformants and images were obtained after 34 h of growth at 37 ◦C.
5. Conclusions
It is striking that the purine de novo pathway is highly conserved between yeast
and human (although some enzymes are much more divergent than others), while the salvage pathway
shows much more differences between these species (Figure 1). However, despite these specific
enzyme differences, several examples reported here reveal a very strong functional conservation,
hence highlighting that similar mechanisms ensure homeostasis in both organisms. This functional
conservation operates both at the metabolic molecular level, i.e., purine nucleotide content and balance,
but also more widely at the cellular or organism level, as revealed by phenotypical outcomes. Due to
this highly functional conservation, yeast, which is prone to genetics, proteomic and metabolic studies,
provides an interesting model to elaborate new working hypotheses testable in human cells or animal
models. In particular, because of the high redundancy of metabolic pathways, combinations of mutants
are often required to reveal phenotypes, and while the construction of double or triple mutants is
trivial in yeast, it is still challenging in most eukaryote organisms.
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Appendix A
Table A1. List of the Saccharomyces cerevisiae purine pathway enzymes shown in Figure 1. Enzyme
features were obtained from the Saccharomyces Genome Database website [62].
Protein Name ORF Name Enzymatic Activities
Aah1 YNL141W Adenine deaminase
Ade1 YAR015W Phosphoribosyl aminoimidazole succinocarboxamide synthetase
Ade12 YNL220W Adenylosuccinate synthase
Ade13 YLR359W Adenylosuccinate lyase
Ade16 YLR028C AICAR transformylase and IMP cyclohydrolase
Ade17 YMR120C AICAR transformylase and IMP cyclohydrolase
Ade2 YOR128C Phosphoribosylaminoimidazole carboxylase
Ade4 YMR300C Phosphoribosylpyrophosphate amidotransferase
Ade5,7 YGL234W Aminoimidazole ribonucleotide synthetase and glycinamideribotide synthetase
Ade6 YGR061C Formylglycinamidine-ribonucleotide synthetase
Ade8 YDR408C Phosphoribosyl-glycinamide transformylase
Adk1 YDR226W Adenylate kinase
Adk2 YER170W Adenylate kinase
Ado1 YJR105W Adenosine kinase
Amd1 YML035C AMP deaminase
Apt1 YML022W Adenine phosphoribosyltransferase
Gua1 YMR217W GMP synthase
Gud1 YDL238C Guanine deaminase
Guk1 YDR454C Guanylate kinase
Hpt1 YDR399W Hypoxanthine-guanine phosphoribosyltransferase
Imd2 YHR216W Inosine monophosphate dehydrogenase
Imd3 YLR432W Inosine monophosphate dehydrogenase
Imd4 YML056C Inosine monophosphate dehydrogenase
Isn1 YOR155C Inosine monophosphate specific nucleotidase
Phm8 YER037W GMP, UMP and CMP nucleotidase
Pnp1 YLR209C Purine nucleoside phosphorylase
Prs1 YKL181W PRPP synthetase subunit
Prs2 YER099C PRPP synthetase subunit
Prs3 YHL011C PRPP synthetase subunit
Prs4 YBL068W PRPP synthetase subunit
Prs5 YOL061W PRPP synthetase subunit
Rnr1 YER070W Large subunit of ribonucleotide-diphosphate reductase
Rnr2 YJL026W Small subunit of ribonucleotide-diphosphate reductase
Rnr3 YIL066C Large subunit of ribonucleotide-diphosphate reductase
Rnr4 YGR180C Small subunit of ribonucleotide-diphosphate reductase
Ynk1 YKL067W Nucleoside diphosphate kinase
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Table A2. List of the human purine pathway enzymes shown in Figure 1. Enzyme features were
obtained from the NCBI web site [63].
Protein Name Gene Location Enzymatic Activity
ADA 20q13.12 Adenosine deaminase
ADK 10q22 Adenosine kinase
ADSL 22q13.1 Adenylosuccinate lyase
ADSS 1q44 Adenylosuccinate synthase
AK1 9q34.11 Adenylate kinase
AK2 1p35.1 Adenylate kinase
AK3 9p24.1 Adenylate kinase
AK4 1p31.3 Adenylate kinase
AK5 1p31.1 Adenylate kinase
AK6 5q13.2 Adenylate kinase
AK7 14q32.2 Adenylate kinase
AK8 9q34.13 Adenylate kinase
AK9 6q21 Adenylate kinase
AMPD1 1p13.2 Adenosine monophosphate deaminase
AMPD2 1p13.3 Adenosine monophosphate deaminase
AMPD3 11p15.4 Adenosine monophosphate deaminase
APRT 16q24.3 Adenine phosphoribosyltransferase
ATIC 2q35 Amino-Imidazole CarboxAmide Ribonucleotide transformylaseand IMP cyclohydrolase
GAH 9q21.13 Guanine deaminase
GART 21q22.11
Phosphoribosylglycinamide formyltransferase,
phosphoribosylglycinamide synthetase
and phosphoribosylaminoimidazole synthetase
GMPS 3q25.31 Guanine monophosphate synthase
GUK1 1q42.13 Guanylate kinase
GUK2 1q32.1-q42 Guanylate kinase
HPRT1 Xq26.1 Hypoxanthine phosphoribosyltransferase
IMPDH1 7q32.1 Inosine monophosphate dehydrogenase
IMPDH2 3p21.31 Inosine monophosphate dehydrogenase
NME1 17q21.33 Nucleoside diphosphate kinase
NME2 17q21.33 Nucleoside diphosphate kinase
NME3 16p13.3 Nucleoside diphosphate kinase
NME4 16p13.3 Nucleoside diphosphate kinase
NME5 5q31.2 Nucleoside diphosphate kinase
NME6 3p21.31 Nucleoside diphosphate kinase
NME7 1q24.2 Nucleoside diphosphate kinase
PAICS 4q12 Phosphoribosylaminoimidazole carboxylaseand phosphoribosylaminoimidazolesuccinocarboxamide synthetase
PFAS 17p13.1 Phosphoribosylformylglycinamidine synthase
PNP 14q11.2 Purine nucleoside phosphorylase
PPAT 4q12 Phosphoribosyl pyrophosphate amidotransferase
PRPS1 Xq22.3 Phosphoribosyl pyrophosphate synthetase 1
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Table A2. Cont.
Protein Name Gene Location Enzymatic Activity
PRPS2 Xp22.2 Phosphoribosyl pyrophosphate synthetase 2
RRM1 11p15.4 Ribonucleotide reductase catalytic subunit
RRM2 2p25.1 Ribonucleotide reductase regulatory subunit
RRM2B 8q22.3 Ribonucleotide reductase regulatory subunit
XDH 2p23.1 Xanthine dehydrogenase/oxidase
Table A3. Comparison of the yeast and human purine pathway enzymes depicted in Figure 1.
Identity and similarity scores were obtained from the ProteomeTM platform [64]. For each enzymatic
activity, only the best score obtained between yeast and a human ortholog was shown. Protein coverage
refers to the fraction (%) of the entire protein (the smallest of the two orthologs) used in the alignment
for determination of identity and similarity scores.
Yeast Protein Human Protein Identity (%) Similarity (%) Protein Coverage (%)
Rnr2 RMM2 69 81 90
Rnr3 RMM1 66 84 87
Ade13 ADSL 64 79 97
Prs3 PRPS2 61 78 79
Ynk1 NME2 61 80 97
Imd2 IMPD2 61 78 98
Prs2 PRPS1 60 75 78
Ade16 ATIC 60 75 99
Ade17 ATIC 60 75 99
Adk1 AK2 58 73 98
Ade12 ADSS 52 68 99
Pnp1 PNP 51 68 85
Guk1 GUK1 51 70 99
Amd1 AMPD2 50 66 74
Ade5,7 GART 45 64 99
Apt1 APRT 44 64 96
Gud1 GAH 42 49 99
Ado1 ADK1 36 57 99
Gua1 GMPS 36 54 100
Ade4 ATASE/PPAT 34 51 92
Ade6 PFAS 33 49 99
Hpt1 HGPRT 33 46 33
Ade8 GART 32 52 92
Ade2 PAICS 27 45 99
Ade1 PAICS 22 41 100
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